# US 2003/0232845 A1 · Xanthine phosphodiesterase V inhibitor polymorphs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232845 A1
- Document ID: US20030232845A1
- Status: Published application
- Kind: A1
- Application number: 10/449,650
- Filed: 2003-05-30
- Published: 2003-12-18
- Earliest claimed: 2002-05-31
- Assignees: Schering Corporation
- Inventors: Vilas H. Dahanukar; Hoa N. Nguyen; Cecilia A. Orr; Funcheng Zhang; Ilia A. Zavialov; Kevin Klopfer; Jeffrey M. Skell; Albert W. Buchholz JR.; Craig D. Boyle
- Web page: https://patentgrep.com/patent/US20030232845A1

## CPC

- C07D 473/04: two oxygen atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Crystalline polymorphs of 1-ethyl-3,7-dihydro-8-[(1R,2R)-(hydroxycyclopentyl)amino]-3-(2-hydroxyethyl)-7-[(3-bromo-4-methoxyphenyl)methyl]-1H-Purine-2,6-dione in Form 1 and Form 2, which exhibit x-ray powder diffraction profiles substantially the same as those shown in FIGS. 5 and 6, respectively, and which exhibit differential scanning calorimtery profiles substantially the same as those shown in FIGS. 2 and 4, respectively, and are represented by the formula: 1 Pharmaceutical compositions comprising the polymorph Form 1 or 2 of Compound 13 and at least one excipient or carrier, and methods of using the polymorph Form 1 or 2 of Compound 13 to treat a variety of physiological disorders, such as erectile dysfunction.

## Claims

### Claim 1

A crystalline polymorph Form 2 of Compound 13:
9
that exhibits an x-ray powder diffraction pattern having characteristic peak locations of 8.1, 11.3, 17.2, and 22.2 degrees 2θ+/−0.5 degrees 2θ.

### Claim 2 (depends on 1)

The crystalline polymorph of claim 1 that exhibits an x-ray powder diffraction pattern having characteristic peak locations of 8.1, 11.3, 13.1, 15.3, 16.1, 17.2, 17.6, 18.9, 20.9, 21.8, 22.2, 23.4 24.1, 25.8 and 30.6 degrees 2θ+/−0.5 degrees 2θ.

### Claim 3 (depends on 1)

The crystalline polymorph of claim 1 that exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 5.

### Claim 4 (depends on 1)

The crystalline polymorph of claim 1 that exhibits a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in FIG. 2.

### Claim 5 (depends on 1)

The crystalline polymorph of claim 1, which is prepared by crystallizing Compound 13 in an essentially non-aqueous solvent.

### Claim 6 (depends on 5)

The crystalline polymorph of claim 5, wherein the essentially non-aqueous solvent is an organic solvent selected from the group consisting of alcohols, nitrites, esters, ketones, and mixtures thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the crystalline according to claim 1, and at least one excipient or carrier.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7 further comprising at least one compound selected from the group consisting of: a prostanoid, α-adrenergic receptor, dopamine receptor agonist, melanocortin receptor agonist, endothelin receptor antagonist, endothelin converting enzyme inhibitor, angiotensin 11 receptor antagonist, angiotensin converting enzyme inhibitor, neutral metalloendopeptidase inhibitor, renin inhibitor, serotonin 5-HT2c, receptor agonist, nociceptin receptor agonist, rho kinase inhibitor, potassium channel modulator and multidrug resistance protein 5 inhibitor.

### Claim 9 (depends on 1)

A method for treating a physiological disorder, symptom or disease in a patient in need of the treatment, comprising administering to the patient an effective amount of the crystalline polymorph according to claim 1, wherein the physiological disorder, symptom or disease is urogenital, cardiovascular, cerebrovascular, peripheral vascular, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, respiratory tract, allergic associated with atopy, pulmonary hypertension, ischemic heart, impaired glucose tolerance, diabetes and its related complications, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, glomerular, renal insufficiency, nephritis, tubular interstitial, autoimmune, glaucoma, intestinal motility, cachexia or cancer.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the physiological disorder is urogenital.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the urogenital disorder is erectile dysfunction.

### Claim 12 (depends on 1)

A method for elevating a cGMP level in a patient in need of the elevation, comprising administering to the patient an effective amount of the crystalline polymorph according to claim 1.

### Claim 13 (depends on 11)

The method of claim 11 further comprising administering to the patient an effective amount of at least one compound selected from the group consisting of: a prostanoid, α-adrenergic receptor, dopamine receptor agonist, melanocortin receptor agonist, endothelin receptor antagonist, endothelin converting enzyme inhibitor, angiotensin 11 receptor antagonist, angiotensin converting enzyme inhibitor, neutral metalloendopeptidase inhibitor, renin inhibitor, serotonin 5-HT2c receptor agonist, nociceptin receptor agonist, rho kinase inhibitor, potassium channel modulator and multidrug resistance protein 5 inhibitor.

### Claim 14

A crystalline polymorph Form 1 of Compound 13:
10
that exhibits an x-ray powder diffraction pattern having characteristic peak locations of 7.3, 9.2 and 20.2 degrees 2θ+/−0.5 degrees 2θ.

### Claim 15 (depends on 14)

The crystalline polymorph of claim 14 that exhibits an x-ray powder diffraction pattern having characteristic peak locations of 7.3, 8.4, 9.2, 12.7, 14.3, 15.0, 15.4, 16.5, 18.8, 20.2, 20.9, 24.0, 25.8, 26.4, 27.2, 27.6, 29.3, 31.9 and 34.6 degrees 2θ+/−0.5 degrees 2θ.

### Claim 16 (depends on 14)

The crystalline polymorph of claim 14 that exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 6.

### Claim 17 (depends on 14)

The crystalline polymorph of claim 14 that exhibits a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in FIG. 4.

### Claim 18 (depends on 14)

The crystalline polymorph of claim 14, which is prepared by crystallizing Compound 13 by dissolving it in an organic solvent, and adding water thereto.

### Claim 19 (depends on 18)

The crystalline polymorph of claim 18, wherein the organic solvent is selected from the group consisting of alcohols, nitriles, esters, ketones, and mixtures thereof.

### Claim 20 (depends on 14)

The crystalline polymorph of claim 14, which is prepared by crystallizing Compound 13 by dissolving it in an ester, and adding an anti-solvent thereto.

### Claim 21 (depends on 20)

The crystalline polymorph of claim 20, wherein the anti-solvent is a hydrocarbon selected from the group consisting of hexane, heptane, toluene and xylene.

### Claim 22 (depends on 14)

A pharmaceutical composition comprising the crystalline polymorph according to claim 14, and at least one excipient or carrier.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22 further comprising at least one compound selected from the group consisting of: a prostanoid, α-adrenergic receptor, dopamine receptor agonist, melanocortin receptor agonist, endothelin receptor antagonist, endothelin converting enzyme inhibitor, angiotensin 11 receptor antagonist, angiotensin converting enzyme inhibitor, neutral metalloendopeptidase inhibitor, renin inhibitor, serotonin 5-HT2c receptor agonist, nociceptin receptor agonist, rho kinase inhibitor, potassium channel modulator and multidrug resistance protein 5 inhibitor.

### Claim 24 (depends on 14)

A method for treating a physiological disorder, symptom or disease in a patient in need of the treatment, comprising administering to the patient an effective amount of the crystalline polymorph according to claim 14, wherein the physiological disorder, symptom or disease is urogenital, cardiovascular, cerebrovascular, peripheral vascular, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, respiratory tract, allergic associated with atopy, pulmonary hypertension, ischemic heart, impaired glucose tolerance, diabetes and its related complications, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, glomerular, renal insufficiency, nephritis, tubular interstitial, autoimmune, glaucoma, intestinal motility, cachexia or cancer.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the physiological disorder is urogenital.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the urogenital disorder is erectile dysfunction.

### Claim 27 (depends on 14)

A method for elevating a cGMP level in a patient in need of the elevation, comprising administering to the patient an effective amount of the crystalline polymorph according to claim 14.

### Claim 28 (depends on 26)

The method of claim 26 further comprising administering to the patient an effective amount of at least one compound selected from the group consisting of: a prostanoid, α-adrenergic receptor, dopamine receptor agonist, melanocortin receptor agonist, endothelin receptor antagonist, endothelin converting enzyme inhibitor, angiotensin 11 receptor antagonist, angiotensin converting enzyme inhibitor, neutral metalloendopeptidase inhibitor, renin inhibitor, serotonin 5-HT2c receptor agonist, nociceptin receptor agonist, rho kinase inhibitor, potassium channel modulator and multidrug resistance protein 5 inhibitor.
